Veraxa Biotech AG - Post de-SPAC (VRXA) Cash from Operations (2025)
Veraxa Biotech AG - Post de-SPAC's (VRXA) quarterly Cash from Operations came in at $1251.2 in Q4 2025.
Powered by 
Analysis
Veraxa Biotech AG - Post de-SPAC (VRXA) Cash from Operations (2025) Analysis & Trends
Veraxa Biotech AG - Post de-SPAC (VRXA) has reported Cash from Operations for 1 consecutive years, with $1251.2 the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -270.50 Mn |
| 10 | Veraxa Biotech AG - Post de-SPAC | 23.88 Mn | 20.47 Mn | - | 1,251.17 |